SCHEMBL25857038

SCHEMBL25857038

N/C(=N\C(=O)Nc1ccccn1)Nc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.60
RAB9A P51151 8/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
PKM P14618 2/20 0.60
ADORA3 P0DMS8 1/20 0.60
PIM1 P11309 1/20 0.60
ADORA2A P29274 1/20 0.60
ADORA2B P29275 1/20 0.60
ADORA1 P30542 1/20 0.60
FLT3 P36888 1/20 0.60
PIM3 Q86V86 1/20 0.60
AURKB Q96GD4 1/20 0.60
ADRA2A P08913 1/20 0.52
ADRA2B P18089 1/20 0.52
ADRA2C P18825 1/20 0.52
HDAC3 O15379 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC1 Q13547 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25857032 0.91 RAB9A (0.58) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL24746975 0.82 GRIN2D (0.55) NPC1RAB9ASMN1; SMN2KMT2AADRA2A
SCHEMBL9317689 0.76 RAB9A (1.00) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL24747095 0.76 GRIN2D (0.52) NPC1RAB9ASMN1; SMN2KMT2AADRA2A
SCHEMBL1486005 0.76 NPC1 (0.63) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL25857027 0.74 KDM1A (0.50) SMN1; SMN2KMT2AADRA2ALMNAGAA
SCHEMBL438214 0.73 RAB9A (0.70) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL23069068 0.73 RAB9A (0.87) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL519066 0.71 RAB9A (0.73) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL4564658 0.71 RAB9A (0.61) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11801228-B2 Modified guanidine-containing polymers for biologic delivery THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2023-10-31 US disclosed
US-20230225982-A1 MODIFIED GUANIDINE-CONTAINING POLYMERS FOR BIOLOGIC DELIVERY THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230225982-A1 MODIFIED GUANIDINE-CONTAINING POLYMERS FOR BIOLOGIC DELIVERY GMPS, RNMT, GUCY1A1 NPC1 1081/4885RAB9A 1420/4885SMN1; SMN2 2647/4885
US-11801228-B2 Modified guanidine-containing polymers for biologic delivery GMPS, RNMT, GUCY1A1 NPC1 1081/4885RAB9A 1420/4885SMN1; SMN2 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.